Literature DB >> 15203798

Effects of quitting smoking on EEG activation and attention last for more than 31 days and are more severe with stress, dependence, DRD2 A1 allele, and depressive traits.

David Gilbert1, Joseph McClernon, Norka Rabinovich, Chihiro Sugai, Louisette Plath, Greg Asgaard, Yantao Zuo, Jodi Huggenvik, Nazeih Botros.   

Abstract

Changes in physiology and attentional performance associated with smoking abstinence were characterized in 67 female smokers during low-stress and high-stress conditions. Abstinence was associated with decreases in cognitive performance, heart rate, and electroencephalographic (EEG) activation but with no change in serum estradiol or progesterone. Effects of quitting showed no tendency to resolve across the 31 days of abstinence. EEG deactivation and heart rate slowing were greater during a math task (high stress) than during relaxation (low stress). Individuals high in trait depression or nicotine dependence or with at least one dopamine D(2) receptor A1 allele experienced greater EEG deactivation following abstinence, especially in the right hemisphere during the stressful task. Thus, findings support the situation x trait adaptive response model of abstinence effects and emphasize the value of multiple dependent measures when characterizing abstinence responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15203798     DOI: 10.1080/14622200410001676305

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  40 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  Transdermal nicotine-induced tobacco abstinence symptom suppression: nicotine dose and smokers' gender.

Authors:  Sarah E Evans; Melissa Blank; Cynthia Sams; Michael F Weaver; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2006-05       Impact factor: 3.157

Review 3.  Nicotinic modulation of neuronal networks: from receptors to cognition.

Authors:  Huibert D Mansvelder; Karlijn I van Aerde; Jonathan J Couey; Arjen B Brussaard
Journal:  Psychopharmacology (Berl)       Date:  2005-07-02       Impact factor: 4.530

4.  Polymorphisms in the DBH and DRD2 gene regions and smoking behavior.

Authors:  Maria Teresa M V Freire; Francine Z C Marques; Mara H Hutz; Claiton H D Bau
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-21       Impact factor: 5.270

5.  Smoking impacts on prefrontal attentional network function in young adult brains.

Authors:  Francesco Musso; Franziska Bettermann; Goran Vucurevic; Peter Stoeter; Andreas Konrad; Georg Winterer
Journal:  Psychopharmacology (Berl)       Date:  2006-08-26       Impact factor: 4.530

6.  Ventral striatal blood flow is altered by acute nicotine but not withdrawal from nicotine.

Authors:  Jody Tanabe; Thomas Crowley; Kent Hutchison; David Miller; Glyn Johnson; Yiping P Du; Gary Zerbe; Robert Freedman
Journal:  Neuropsychopharmacology       Date:  2007-04-25       Impact factor: 7.853

7.  The effects of nicotine and non-nicotine smoking factors on working memory and associated brain function.

Authors:  Francis Joseph McClernon; Brett Froeliger; Jed E Rose; Rachel V Kozink; Merideth A Addicott; Maggie M Sweitzer; Eric C Westman; Dana M Van Wert
Journal:  Addict Biol       Date:  2015-04-22       Impact factor: 4.280

8.  Smoking withdrawal shifts the spatiotemporal dynamics of neurocognition.

Authors:  Rachel V Kozink; Avery M Lutz; Jed E Rose; Brett Froeliger; F Joseph McClernon
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

9.  Effects of bupropion sustained release on task-related EEG alpha activity in smokers: Individual differences in drug response.

Authors:  Jian Zhu; Ryan P Coppens; Norka E Rabinovich; David G Gilbert
Journal:  Exp Clin Psychopharmacol       Date:  2017-02       Impact factor: 3.157

10.  Hostility, cigarette smoking, and responses to a lab-based social stressor.

Authors:  Christopher W Kahler; Adam M Leventhal; Suzanne M Colby; Chad J Gwaltney; Thomas W Kamarck; Peter M Monti
Journal:  Exp Clin Psychopharmacol       Date:  2009-12       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.